APC+/− alters colonic fibroblast proteome in FAP by Patel, Bhavinkumar B. et al.
www.impactjournals.com/oncotarget/  Oncotarget, March, Vol.2, No 3
Oncotarget 2011; 2:  197 - 208 www.impactjournals.com/oncotarget 197
APC+/- alters colonic fibroblast proteome in FAP
Bhavinkumar B. Patel1*, Xin-Ming Li1*, Maketa P. Dixon1, Elena L. Blagoi1, 
Emmanuelle Nicolas1, Steven H. Seeholzer1, David Cheng1, Yin A. He1, Renata 
A. Coudry2, Sharon D. Howard5, Dawn M. Riddle4, Harry S. Cooper2, Bruce M. 
Boman5, Peggy Conrad6, James A. Crowell7, Alfonso Bellacosa3, Alfred Knudson3, 
Anthony T. Yeung1, and Levy Kopelovich7
1 Developmental Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
2 Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, Pennsylvania
3 Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
4 Cell Culture facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania
5 Division of Genetic and Preventive Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania
6 University of California at San Francisco, San Francisco, California
7 Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
* These authors contributed equally to this manuscript
Correspondence to: Anthony T. Yeung, email: Anthony.Yeung@fccc.edu
Correspondence to: Levy Kopelovich, email: kopelovl@mail.nih.gov
Keywords: Adenomatous polyposis, APC, tumor suppressor, colon fibroblasts, heterozygosity, proteomics
Received:  December 22, 2010, Accepted: March 15, 2011, Published: March 15, 2011
Copyright: © Patel et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct:
Here  we  compared  the  proteomes  of  primary  fibroblast  cultures  derived  from 
morphologically normal colonic mucosa of familial adenomatous polyposis (FAP) 
patients with those obtained from unaffected controls. The expression signature of 
about  19%  of  total  fibroblast  proteins  separates  FAP  mutation  carriers  from  unaffected 
controls  (P  <  0.01).  More  than  4,000  protein  spots  were  quantified  by  2D  PAGE  analysis, 
identifying  368  non-redundant  proteins  and  400  of  their  isoforms.  Specifically,  all  three 
classes of cytoskeletal filaments and their regulatory proteins were altered as were 
oxidative stress response proteins. Given that FAP fibroblasts showed heightened 
sensitivity to transformation by KiMSV and SV40 including elevated levels of the p53 
protein, events controlled in large measure by the Ras suppressor protein-1 (RSU-1) 
and oncogenic DJ-1, here we show decreased RSU1 and augmented DJ-1 expression 
in both fibroblasts and crypt-derived epithelial cells from morphologically normal 
colonic mucosa of FAP gene-carriers. The results indicate that heterozygosity for 
a mutant APC tumor suppressor gene alters the proteomes of both colon-derived 
normal  fibroblasts  in  a  gene-specific  manner,  consistent  with  a  “one-hit”  effect.
IntroductIon
Abnormal gene expression changes in phenotypically 
normal, cultured epithelial and stromal cells have been 
demonstrated in a number of autosomal dominant cancer 
syndromes, including the Li-Fraumeni syndrome (LFS) 
[1], BRCA1 and 2, [2], the von Hippel-Lindau (VHL) and 
the tuberous sclerosis complex (TSC) [3] and familial 
adenomatous polyposis (FAP) patients [4]. For example, 
FAP mutation carriers are heterozygous for mutations in 
the adenomatous polyposis coli (APC) tumor suppressor 
gene, and wherein the proteome of epithelial cells within 
colonic crypts of normal-appearing colonic mucosa 
differs from that of control individuals with the wild-type 
APC gene [4]. 
Although colon cancer arises from crypt epithelial 
cells, one element of growth regulation of the epithelial 
cells in situ is provided by stromal fibroblasts which form 
a sheath around the colonic crypts. In fact, a tight temporal 
relationship was shown to exist between epithelial and Oncotarget 2011; 2:  197 - 208 198 www.impactjournals.com/oncotarget
stromal cells in the colon epithelio-mesenchymal matrix 
during cell differentiation [5]. Here we showed that the 
proteome of fibroblasts within crypts of normal-appearing 
colonic mucosa of FAP patients differs from wild-type 
APC gene carriers and that these alterations are shared 
by the colonic crypt epithelial cells, consistent with a role 
for mesenchymal-epithelial interaction and possibly a 
harbinger of epithelial mesenchyme transition (EMT) [5, 
6]. These studies should provide more precise molecular 
markers likely unique for APC alterations which would 
enable mechanism-based early detection and personalized 
prevention strategies for colon cancer.
results
characterization of FAP versus controls
Supplemental Data 1 tabulates characteristics of 
patient samples used for the study. Representative 2D gels 
of FAP and control colonic fibroblasts are shown in Figure 
1. Both control and FAP samples were initially used to 
construct a protein and isoform database for the colonic 
fibroblasts  (Supplemental  Data  2–4),  including  mass 
spectrometry identification of about 368 unique protein 
entries and about 400 of their post-translationally modified 
isoforms from 2D gels. Each spot is hyperlinked to a gene 
ontology web site. Size and isoelectric point information 
allowed each spot to be scrutinized for post-translational 
modification.  Point-and-click  searchable  proteomes  for 
the colonic fibroblasts for three pH ranges are provided 
in supplemental data and at our web site. Proteins with 
expression changes are indicated in Supplemental Data 
5–7 and tabulated in Supplemental Data 8. Many of the 
observed protein changes affect pathways of energy 
metabolism, cytoskeleton, proteolysis, protein synthesis, 
or RNA metabolism (Supplemental Data 8). Significant 
FAP-specific  proteomic  changes  in  common  between 
crypt-derived epithelial cells and colonic fibroblasts are 
highlighted in Table 1. 
The cytoskeleton is comprised of three types of 
filaments, each was observed to change in a gene-specific 
way in the FAP fibroblasts. These are the actin filaments, 
the intermediate filaments, and the microtubules (Table 2 
and Supplemental Data 9). 
Actins: Several actin-associated proteins showed 
isoform expression changes (Table 2). Actins with 
Figure 1: 2D gels of FAP and control colonic fibroblasts.Three overlapping pH range 2D gels across pI 4–11 of FAP and 
control colonic fibroblasts. These files are also in the Supplemental Data and at our web site after publication and are searchable and 
hyperlink-enabled to gene ontology on line.
Figure 1. Bhavinkumar Patel et al.Oncotarget 2011; 2:  197 - 208 199 www.impactjournals.com/oncotarget
isoforms  changing  significantly  include  beta  actin  and 
smooth  muscle  actin,  suggesting  that  these  fibroblasts 
are myofibroblasts. Myofibroblasts are implicated in the 
structure and function of colonic crypt [7]. Actin proteins, 
include  filamin-A,  cross-links  actin  filaments  and  can 
affect their structure, strength, and cell proliferation [8]. 
The Septins [9], a family of cytoskeletal GTPases, may 
participate in a protein complex regulating the structure 
and function, elongation, bundling or disruption of the 
actin cytoskeleton and microtubules. Similarly, LASP-1 is 
an important regulatory protein in the actin cytoskeleton 
interacting through the palladin isoforms [10]. Importantly, 
the FAP gene-specific changes in actin filaments activity, 
and cell proliferation is highlighted by alterations in three 
isoforms of caldesmon (Table 2). Caldesmon regulates 
actin-tropomyosin activated myosin MgATPase via 
inhibition of Ca++-dependent smooth muscle contraction 
[11].
The intermediate filaments: The lamin A/C and B1 
isoform changes can regulate the structure and stability of 
the inner nuclear membrane. The vimentin intermediate 
filaments provide mechanical strength to fibroblasts and 
indirectly regulate cell adhesion. Vimentin dynamic 
rearrangement is regulated by dephosphorylation [12]. 
The vimentin changes observed in Table 2 are vimentin 
fragments; the native vimentin level did not appear to 
change. During apoptosis, vimentin is cleaved by multiple 
activated  caspases,  including  caspase-3,  -6  and  –9,  at 
distinct sites to yield proteolytic fragments [13]. Cleavage 
of vimentin also may facilitate nuclear condensation and 
subsequent fragmentation via disruption of the cytoskeletal 
network. The observed vimentin changes may be linked to 
the observed lamin changes in the FAP fibroblasts. Lastly, 
cytoskeletal keratin 7 was observed to up-regulate six fold 
in FAP fibroblasts (Table 2). How this keratin isoform 
induction affects the FAP fibroblasts is not yet clear, but 
its actions may be via cell motility and transformation to 
an epithelial or endothelial phenotype.
The microtubules: Both alpha and beta tubulin 
chains were observed to change in FAP (Table 2). These 
proteins function in a variety of cellular activities and 
are drug targets for cancer treatment [14]. Their role in 
the FAP cytoskeleton may be interactive with at least 15 
isoforms of other proteins that link the cytoskeleton to the 
plasma membrane (listed at the bottom of Table 2). 
Proteins linking the cytoskeleton to membrane 
dynamics up-regulated include Alpha-actinin 4, Annexin 
A1, Integrin-linked protein kinase 1, moesin, zyxin, 
vinculin, rho GDP-dissociation inhibitor 1, T-complex 
protein 1 β subunit, and transgelin (Table 2). 
The changes in cytoskeleton proteome, including 
the induction of a Rho GDP-dissociation inhibitor 1 in 
Table 1: FAP-dependent protein differences found in both crypt epithelial cells & colonic fibroblasts
Colonic 
Fibroblast_FAPfold 
change, control=1
Colonic 
Crypt_FAP 
fold change, 
control=1
ID 2D gel 
pH 
range
Swiss-
Prot ID #
Protein Name Theoretical pI Theoretical 
MW
FAP >2X Control
2.8 4.8 2557 5-8 Q99497 Protein DJ-1 6.3 19891
Only in FAP 
4.4 2097 4-7 P07339 Cathepsin D 5.6 37852
2.0
4.1 1553 5-8 P61163
α-centractin 
(Centractin) 6.2 42614
Only in FAP 
3.2 2165 4-7 P52565
Rho GDP-
dissociation 
inhibitor 1 5.0 23207
10.5/2.6
2.9 1390 5-8 P06733 α-enolase 7.0 47038
Only in FAP 
2.8 1126 5-8 P30101
Protein disulfide-
isomerase A3 5.6 54265
2.9 2.6 1892 4-7 P10768 Esterase D  6.5 31463
2.6
2.1 2454 5-8 P30041 Peroxiredoxin-6 6.0 24904
Control >2X FAP
-2.1
-2.1 2448 5-8 P60174
Triosephosphate 
isomerase  6.5 26538
-3.3
-2.0 2114 5-8 P08758 Annexin A5 4.9 35806Oncotarget 2011; 2:  197 - 208 200 www.impactjournals.com/oncotarget
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Cytoskeleton proteins organized according to functional categories
Actin Filaments
FAP Only 1669 4-7 P60709 Actin, cytoplasmic 1 (Beta-actin) 5.3 41606 60 22
-3.3 1049 5-8 P60709 Actin, cytoplasmic 1 (Beta-actin) 5.3 41606 89 32
FAP Only 2232 4-7 P62736 Actin, aortic smooth muscle  5.2 41775 57 29
-2.4 1048 5-8 P63267 Actin, gamma-enteric smooth muscle 5.3 41643 81 24
-2.5 1578 5-8 O15144 Actin-related protein 2/3 complex 
subunit 2
6.8 34333 77 35
FAP Only 894 4-7 P21333 Filamin A (Alpha-filamin)  5.7 280630 67 10
-2 1897 4-7 P52907 F-actin capping protein alpha-1 
subunit 
5.5 32792 62 37
2.3 1819 4-7 P09493 Tropomyosin 1 alpha chain 4.7 32709 198 54
FAP Only 1736 4-7 P09493 Tropomyosin 1 alpha chain 4.7 32709 113 38
2 1448 4-7 P61163 Alpha-centractin (Centractin)  6.2 42614 88 34
4 532 4-7 Q05682 Caldesmon (CDM) 5.6 93250 101 29
FAP Only 750 4-7 Q05682 Caldesmon (CDM) 5.6 93250 86 25
-5.2 1310 5-8 Q05682 Caldesmon (CDM) 5.6 93250 53 14
9.1 1755 4-7 Q14847 LIM and SH3 domain protein 1 (LAS P-
1) 
6.6 29717 95 44
FAP Only 1815 4-7 Q14847 LIM and SH3 domain protein 1 (LAS P-
1) 
6.6 29717 66 37
-6.3 901 5-8 Q9NVA2 Septin 11 6.4 49267 73 23
2.2 1690 4-7 Q15019 Septin-2 (NEDD5 protein homolog) 6.2 41487 75 31
Intermediate Filaments
2.1 870 4-7 P02545 Lamin A/C (70 kDa lamin) 6.6 74139 211 43
FAP Only 889 4-7 P02545 Lamin A/C (70 kDa lamin) 6.6 74139 222 42
-3.2 658 5-8 P02545 Lamin A/C (70 kDa lamin) 6.6 74139 148 31
2.6 661 4-7 P20700 Lamin B1 5.1 66277 129 30
3.4 1430 4-7 P08670 Vimentin 5.1 53520 219 55
-2.6 1081 4-7 P08670 Vimentin 5.1 53520 148 35
FAP Only 1199 4-7 P08670 Vimentin 5.1 53520 186 39
5.8 1191 4-7 P08729 Keratin, type II cytoskeletal 7  5.5 51287 211 45
Microtubules
FAP Only 1082 4-7 P07437 Tubulin beta-2  chain 4.8 49671 68 21
3.1 1761 4-7 P07437 Tubulin beta-2  chain 4.8 49671 93 19
3 1763 4-7 Q9BQE3 Tubulin alpha-6 chain  5 49895 84 27
FAP Only 1744 4-7 Q9BQE3 Tubulin alpha-6 chain 5 49895 55 20
Proteins link Cytoskeleton and Plasma Membrane
-3.8 396 4-7 P12814 Alpha-actinin 1  5.3 103058 109 21
6.2 429 4-7 O43707 Alpha-actinin 4 5.3 104854 82 18
2.9 1637 5-8 P04083 Annexin A1 6.6 38583 94 35
2.2 1690 4-7 P07355 Annexin A2  7.6 38473 232 53
-3.4 2085 4-7 P08758 Annexin A5  4.9 35806 139 52
-2.6 561 4-7 P15311 Ezrin (p81)  6 69268 150 36
2.4 1321 4-7 Q13418 Integrin-linked protein kinase 1  8.3 51419 75 23
2.3 653 4-7 P26038 Moesin  6.1 67689 200 45
-2.1 961 4-7 P26038 Moesin  6.1 67689 62 20
FAP Only 222 4-7 P18206 Vinculin (Metavinculin) 5.5 123668 125 22
2.1 510 4-7 Q15942 Zyxin (Zyxin 2) 6.2 61277 60 23
FAP Only 2430 4-7 P52565 Rho GDP-dissociation inhibitor 1  5 23076 78 38
FAP Only 1124 4-7 P78371 T-complex protein 1, beta subunit  6 57357 66 18
2.7 2207 5-8 Q01995 Transgelin  8.9 22480 92 40
-5.4 2205 5-8 Q01995 Transgelin 8.9 22480 95 42
Table  2:  Differential  expression  between  FAP  and  normal  fibroblast  primary  cultures.  Cytoskeleton proteins organized 
according to functional categories.Oncotarget 2011; 2:  197 - 208 201 www.impactjournals.com/oncotarget
FAP fibroblasts (Tables 1 & 2), and previous observation 
of Ras-dependent viral transformation sensitivity of FAP 
fibroblasts, focused our interest on a potential role for Ras 
activity which depends on membrane localization [15]. 
Consequently, we investigated the subcellular location 
and levels of the Ras suppressor protein RSU1 in the 
colonic  fibroblasts.  The  confocal  immunofluorescence 
image in Supplemental Data 10 indicated that RSU1 
antigen is largely associated with the plasma membranes 
in  FAP  fibroblasts  whereas  most  of  the  APC  protein 
appeared nuclear. Collectively our proteomic data 
illustrate profound cytoskeletal changes in FAP fibroblasts 
in a gene-specific manner.
Measurement of RSU1 expression
Consistent with a potential increase in Ras activity 
[16] we focused on RSU-1 that is a prime regulator of ras 
[17]. Validation of this potentially important biomarker, 
RSU1 was performed on morphologically normal crypt-
derived  epithelial  cells  and  primary  fibroblast  cultures 
both from the morphologically normal mucosa of FAP 
gene carriers and unaffected controls (Figure 2). Spot 
2474, identified as RSU1, averaged more than two-fold 
greater abundance in four control fibroblasts than in four 
FAP fibroblasts (Supplemental Data 11). The RSU1 spot, 
observed in the pH 5–8 gel, has the theoretical mass, yet its 
pI suggests that it may be a phosphorylated protein. Upon 
identification of all visible protein spots in this region of 
a pH 6–11 gel, four RSU1 isoforms of approximately the 
same size were identified (Figure 2A). These RSU1 spots 
in four 2D gels of FAP versus four gels of controls were 
quantified by densitometry scanning and the results are 
shown in Supplemental Data 12. The two RSU1 spots on 
the left side of the gel, significantly decreased in intensities 
in FAP cells (not detectable in FAP and 2.5 fold lower 
in FAP than control, respectively), show pI’s consistent 
Figure 2: RSU-1 expression in colonic fibroblasts. A. pH 6–11 range 2D gel analysis of RSU-1 protein isoforms in control colon 
fibroblasts. All the protein spots observed in this picture were identified with mass spectrometry. Four isoforms of RSU-1 are indicated by the 
arrows. The rightmost spot is unmodified RSU-1. The second spot from the left is lower in intensity in FAP fibroblasts. The right two RSU-1 
spots were outside of the range of the pH 5–8 gels previously used to detect changes in RSU-1 levels. B. Western analysis of RSU1 expression 
in FAP colonic fibroblasts versus control colonic fibroblasts. C. Western analysis of RSU-1 expression in FAP colonic crypt cells versus those 
from control patients.
Figure 2. Bhavinkumar Patel et al.Oncotarget 2011; 2:  197 - 208 202 www.impactjournals.com/oncotarget
with  modification  by  post-translational  modifications, 
including but not limited to phosphorylation events. 
RSU1 isoforms can also arise from alternate mRNA 
splice forms [18] and SNPs. The isoforms of different 
patients has slightly different electrophoretic mobilities 
(data not shown). Total RSU1 expression was lower in all 
six FAP fibroblast samples compared to non-FAP control 
fibroblasts (Figure 2B). RSU1 levels were also lower in the 
morphologically normal epithelial cell from FAP crypts 
than in control crypts (Figure 2C). It is also likely that 
RSU1 protein has more than one function in the cell, and 
a subset of this protein is modified in the FAP phenotype, 
wherein the lower level has potential to enhance the 
relative activity of the endogenous Ras oncogene.
Oxidative Stress Response in FAP fibroblasts
The FAP fibroblasts exhibit an enhanced oxidative 
stress response (Table 3). Examples include elevation of 
Alpha crystallin B chain which is a heat shock protein that 
accumulates after oxidative stress conferring resistance to 
TNF and oxidative stress in murine fibroblasts [19] , Other 
examples include Tropomyosin-1 which is phosphorylated 
at Ser283 through the Erk/DAPK pathway and promotes 
stress  fiber  formation  in  response  to  oxidative  stress 
[20], and DJ-1. Yet another FAP-elevated protein 
is Peroxiredoxin-6, a phospholipase which protects 
mitochondria from ischemia and oxidative stress [21], by 
acting as the substrate for hyperoxidation [22]. Both DJ-1 
and peroxiredoxin-6 are elevated in FAP colonic fibroblast 
cultures and in FAP crypt epithelial cells (Table 1[4]).
Measurement of DJ-1 expression
Our previous data on the potential role of p53 and 
oxidative stress [4] has also led us to focus on the role of 
another potential FAP biomarker, DJ-1. A DJ-1 isoform 
(Figure 3) identified as spot 2549 (in pH 4–7 gel) was up-
regulated by 4.8-fold in FAP crypts-derived epithelial cells 
compared with controls (Supplemental Data 8) and up-
regulated 2.8-fold in FAP colonic fibroblast cultures versus 
control cultures (Supplemental Data 13). Experiments 
using Western blots were performed to investigate DJ-1 
expression changes in colonic crypts versus wild-type 
samples. Figure 3 illustrates the importance of identifying 
the protein spots that showed little change between cases 
and controls, and the need to follow through with 2D 
gel Western blot characterization. Not all isoforms of a 
given protein may show proteomic changes and some 
isoforms may be hidden by other co-migratory proteins. 
Alternatively, two isoforms of a protein may show 
reciprocal changes in expression. The level of DJ-1 did 
Table 3: Differential expression between FAP and normal fibroblast primary cultures in response to oxidative stress. Both 
DJ-1 and Peroxiredoxin-6 were up-regulated in both FAP crypt and fibroblast.
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Proteins involved in response to oxidative stress.
FAP >2X Control
4.1 2089 5-8 P02511
Alpha crystallin B chain 
(Rosenthal fiber component)  6.8 20159 138 46
2.8 2549 4-7 Q99497 DJ-1 protein (Oncogene DJ1) 6.3 19891 102 65
2.6 2388 4-7 P30041
Peroxiredoxin 6 (Antioxidant 
protein 2)  6.0 24904 100 42
2.3 1819 4-7 P09493
Tropomyosin 1 alpha chain 
(Alpha-tropomyosin) 4.7 32709 198 54
4.1 2089 5-8 P02511
Alpha crystallin B chain 
(Rosenthal fiber component) 6.8 20159 138 46
2.8 2549 4-7 Q99497 DJ-1 protein (Oncogene DJ1) 6.3 19891 102 65
Protein Found Only in FAP
- 1736 4-7 P09493
Tropomyosin1 alpha chain
(Alpha-tropomyosin) 4.7 32709 113 38Oncotarget 2011; 2:  197 - 208 203 www.impactjournals.com/oncotarget
not change as judged by 1D gel Western blotting (Figure 
3A).  Although  2D  gel  protein  identification  by  mass 
spectrometry only revealed two isoforms of DJ-1 (Figure 
3B), 2D gel Western blotting experiment revealed at least 
four isoforms of DJ-1 (Figure 3C). The heaviest spot 1 on 
the right side represents the theoretical pI and molecular 
weight of the unmodified DJ-1 protein. Change in this 
spot was not detected in 2D gel images. However, spot 2 
showed a pI value consistent with an increase of a post-
translational modification, including but not limited to a 
phosphorylation event, in the protein molecule. This spot 
showed slight elevation in FAP samples. Spot 3 is the spot 
detected as up-regulated by about 3–4 fold in FAP crypt 
cells and in FAP fibroblasts. Spot 4 was also increased 
in FAP samples, but undetected in 2D gels by protein 
staining because it was hidden under a protein of greater 
abundance. 
Regulation of RSU1 and DJ-1 gene expression
Whether RSU1 was regulated at the mRNA level in 
colonic fibroblasts was investigated by using quantitative 
real-time PCR. The transferrin receptor gene (TFRC) 
was used as the normalization gene. Results are shown 
in Supplemental Data 14. The fold protein levels of two 
RSU1 protein isoforms in FAP fibroblast ranged from not 
detectable in FAP to 2.5 fold lower in FAP than control, 
respectively (Supplemental Data 12B), and about 2.5 fold 
lower than control in Western blotting analysis (Figure 
2B), and the mRNA level of RSU1 was on average 1.15 ± 
0.38 for control and 0.88 ± 0.15 for FAP relative to TFRC. 
This may suggests that expression of the RSU1 protein 
is regulated primarily post-translationally. A similar 
pattern is seen with DJ-1, wherein the DJ-1 mRNA level 
was statistically non-distinguishable by real-time PCR 
when six FAP fibroblast samples were compared with six 
controls (control mean Ct = 26.4, standard error = 0.325. 
FAP mean Ct = 26.3, standard error = 0.498) (Data not 
shown). In contrast, the protein level change of the DJ-1 
isoform spot 3 was 3 to 4 fold greater in FAP fibroblasts.
dIscussIon
We  recently  reported  proteome  changes  in  crypt-
derived epithelial cells isolated from normal appearing 
colonic mucosa of FAP patients versus control individuals 
[4]. About 13% of the protein spots in 2D gels were 
observed to shift in intensity and the changes resided mainly 
among isoforms of each protein [4]. Crypt epithelial cells 
are sheathed by and interactive with colonic fibroblasts 
Figure 3. Bhavinkumar Patel et al.
Figure 3: DJ-1 proteomic changes in colonic crypts. A. 1D gel Western blotting, B. 2D gel pH4–7 12% SDS-PAGE gels, and mass 
spectrometry protein identification, and C. 2D gel Western blotting experiments. The circled protein spots were DJ-1 identified by mass 
spectrometry. Corresponding spots were indicated by arrows in the 2D Western blotting images. For the 2D Western, Control was CP 203, FAP 
was SID 516. Oncotarget 2011; 2:  197 - 208 204 www.impactjournals.com/oncotarget
[23]. The epithelial-mesenchymal matrix of the colon may 
play a major role during colorectal cancer progression, 
including the development of desmoid tumors that are 
prevalent in FAP patients, especially those with the 
Gardner variant [24]. To increase our understanding, we 
analyzed FAP-dependent protein changes in the colonic 
fibroblasts for systemic expression that may be linked to a 
FAP-specific phenotype.
Previously, we have demonstrated a disruption 
of  overall  actin  organization  in  skin  fibroblasts  from 
FAP patients [25], including increased sensitivity to 
transformation  by  KiMSV  and  SV-40,  and  increased 
expression of the p53 protein [26-28]. Accordingly, we 
have focused on two proteins in our present database 
that are mechanistically important to such transformation 
and potentially relevant to the FAP phenotype; the Ras 
suppressor protein (RSU1) and the DJ-1 oncogene. 
RSU1, so named because its absence led to v-Ras 
transformation in mouse cells, is reported to enhance 
Erk-2 activation, inhibit Jun kinase activation [29], and 
inhibit  anchorage-independent  growth  of  MCF7  cells 
[30]. More recently, full-length 33 KDa RSU1, but not a 
29 KDa truncated form, was shown to bind to the LIM5 
domain of the adaptor protein PINCH1 and to participate 
in adhesion-related functions [31]. Moreover, the 29 
KDa form is elevated in cancer cell lines where Ras is 
activated.  When  cells  were  transformed  with  activated 
Ras, the RSU1 association with ILK and PINCH decreased 
and cell migration increased [32]. ILK expression was 
reported to be greatly elevated in the abnormal crypts from 
polyps of FAP patients [33]. The relationship of RSU1-
ILK-PINCH1 interaction in the crypts and the potential 
role of RSU1 in cell migration are yet to be established. 
Interestingly, the APC protein itself has been implicated in 
cell-cell adhesion
Ceramide, a pro-apoptotic agent, has been shown 
to induce RSU1, presumably by directly suppressing Ras 
expression  [34].  Significantly,  we  showed  that  RSU1 
expression  was  decreased  in  both  FAP  fibroblasts  and 
crypt epithelial cells, more dramatically in the former 
than the latter. Obviously, the decrease in RSU1 levels 
would allow enhanced endogenous Ras activity. The 
higher endogenous Ras activity may decrease ceramide-
induced apoptosis and explain, in part, the 100- to 
1000-fold enhanced sensitivity of the FAP fibroblasts to 
transformation  by  KiMSV  by  allowing  full  expression 
of the v-Ki-ras oncogene [26]. Consistent with the anti-
apoptotic theme is the congruent observation of an 
isoform of Rho GDP-dissociation inhibitor 1 in FAP 
fibroblasts only and its elevation by 3.2 fold in FAP crypt 
when compared with control (Table 1). Elevation in this 
protein was shown to provide cancer cells with resistance 
to drug-induced apoptosis [35]. 
The second protein we focused on, DJ-1, has an 
isoform that is elevated by about three fold in fibroblasts 
and  about  five  fold  in  crypt  epithelial  cells  in  a  FAP 
specific  manner  (Table  1).  DJ-1  has  multiple  known 
functions  (CAP1/RS/PARK7).  It  was  originally  cloned 
as a putative oncogene capable of transforming NIH-3T3 
cells in cooperation with H-ras [36]. DJ-1 is an integral 
mitochondrial protein and is a redox-dependent molecular 
chaperone that inhibits α-synuclein aggregate formation 
[37]  and  in  the  unfolded  protein  response  countering 
protein damage from cigarette smoke in the human lung 
[38]. Recent research also implicated DJ-1 as important in 
lung [39] and prostate cancers [40]. Increased DJ-1 was 
of particular interest to us because our previous proteomic 
study in FAP crypts revealed an elevation of oxidative 
stress response and attenuation of apoptosis [4]. This 
DJ-1 elevation, linked to oxidative stress, is corroborated 
by the elevation of protein disulfide-isomerase A3 and 
peroxiredoxin-6  (Table  1).  Protein  disulfide-isomerase 
A3, uniquely present in FAP fibroblasts, and about three 
fold elevated in FAP crypts compared with control (Table 
1) is needed to renature proteins that have been damaged 
by oxidative stress. Peroxiredoxin-6 (antioxidant protein 
2), 2.6 fold elevated in colonic fibroblasts and 2.1 fold 
elevated in colonic crypts, is an anti-oxidative protein 
with phospholipase A2 activity that can promote the 
invasiveness of lung cancer cells [41]. 
Importantly, DJ-1 appears to have both positive 
and negative effects on p53 transcription. The caspase-6-
derived C-terminal fragment of DJ-1 has been proposed 
to account for DJ-1 associated p53-dependent cell death 
[42]. Sumoylation of DJ-1 was also reported to repress 
p53 transcription [43]. On the other hand, sumoylation 
of DJ-1 and p53 reactivates p53 transcription through a 
Topors/p53BPs complex [44]. These mechanisms might 
be responsible for the increased stability of the p53 protein 
in skin fibroblasts from FAP patients due to elevation of 
oxidative stress response as an early event during cancer 
progression [28]. Furthermore, the increased availability 
of p53 in FAP may explain, in part, the increased 
sensitivity of FAP cells to transformation by SV-40 [45] 
that is facilitated by direct interaction of p53 and large 
T-antigen [46]. 
Alterations in Ras and p53 appear critical during 
colorectal cancer development, and changes of RSU1 
and DJ-1 shown here may precede and perhaps facilitate 
mutational activation associated with both Ras and p53 
[47]. These alterations are shared by the colonic crypt 
epithelial cells and colonic fibroblasts, consistent with a 
role for mesenchymal-epithelial interaction and possibly 
a harbinger of epithelial mesenchyme transition [5, 
6].  Importantly,  the  fibroblasts  of  a  FAP  patient  were 
observed to undergo spontaneous immortalization [48].
Thus, these alterations may well provide a further 
clarification of optimal targets at the “two-hit” stage of 
cancer development; those revealed in one-hit lesions 
would not include confounding secondary tumor 
effects. Collectively, they appear to be directly related 
to cancer and may be useful as biomarkers for early Oncotarget 2011; 2:  197 - 208 205 www.impactjournals.com/oncotarget
events in colorectal cancer development, leading to the 
identification of molecular targets and agents for cancer 
chemoprevention. 
MATeRiAlS AnD MeTHODS
Clinical specimens
Eleven FAP patients and 15 control subjects 
(Supplemental Data 1) were recruited with approval by 
the Institutional Review Boards of Fox Chase Cancer 
Center (protocol number: 00-852) and Thomas Jefferson 
University (protocol number: 00-0023). The 2D gel 
analysis included three FAP patients (mean age of 39.3 
years, range 23 to 53 years, S.D. 8.8 years) (Supplemental 
Data 1). The controls were obtained with patient consent 
through pinch biopsy specimens of patients with no 
evidence of disease undergoing screening colonoscopy. 
Control patients for 2D gel analysis included three 
patients (mean age of 60 years, range 53 to 73 years, S.D. 
6.5 years). Validation experiments used samples from six 
FAP patients and six control patients that were not used in 
the 2D gel proteomics analyses. FAP cases for validation 
included men and women previously diagnosed with FAP 
and whose corresponding APC gene mutations had been 
documented by DNA sequencing of circulating white 
blood cells (Supplemental Data 1). Because FAP patients 
often undergo colectomy at an early age, but screening for 
sporadic cancer starts at a later age, it was not possible to 
age-match FAP cases with controls.
Preparation of primary colonic fibroblast cultures
Fibroblast cultures were prepared from colonic 
mucosa  of  normal  appearance  verified  by  a  resident 
pathologist. The mucosal layer of colonic biopsy specimens 
was transported on ice in Ham’s F-12 serum-free medium 
containing 100 U/ml penicillin, 100 µg/ml streptomycin, 
10 µg/ml ciprofloxacin, 2.5 µg/ml gentamycin, 2.5 µg/ml 
amphotericin B, and 100 U/ml nystatin. Upon receipt, the 
tissue samples were finely minced, transferred to a 50 ml 
tube containing 15 ml of 0.2% collagenase (Sigma #C-
0130) in the transport medium, and incubated for 1.5 hours 
at 37°C in a rotating water bath. Transport medium (15 
ml) was added to the tube and the cells were collected by 
centrifugation at 1200 × g for 10 minutes. The cell pellet 
was washed four times for five minutes, each time with 25 
ml of transport medium, and once with fibroblast culture 
medium (DMEM supplemented with 15% FBS, 4 mM 
L-glutamine,  110  mg/L  pyruvate,  100  U/ml  penicillin, 
100 µg/ml streptomycin and 10 µg/ml ciprofloxacin). The 
cells were then placed into a T-12.5 cm2 flask pre-coated 
with fetal bovine serum (FBS). The culture was incubated 
at 37°C in 7% CO2. The cells began to adhere after 24 to 
72 hours and spread to the surface of the flask. Both FAP 
and control samples were treated with the same culture 
conditions, including timing for passaging and harvesting. 
Importantly, all the samples were deidentified, including 
notation on carrier or control status, and no significant 
difference in growth or apoptosis among them was noted. 
At harvest, all the cultures were in log phase. Cells were 
harvested at passage 1 or 7 by washing once with 5 ml 
of phosphate buffered saline (PBS) Ca++ and Mg++, then 
adding 3 ml of 0.04% trypsin for approximately 5 minutes 
or until the cells lifted. After adding 5 ml of culture media 
to stop the trypsin, the cells were transferred to a 15 ml 
tube, pelleted at 900 rpm, and washed twice with 10 ml of 
PBS. The cells were counted by using a hemocytometer. 
The final pellet contained about 10 to 15 million cells.
2D gel proteomics
Gels of three overlapping pH ranges (pH 4–7, 5–8, 
and 6–11) were used to display more than 4,000 protein 
spots for each sample (Figure 1). The first dimension was 
performed using IPG strips of pH 4–7, 5–8 (ReadyStrip; 
0.5 × 3 × 170 mm, Bio-Rad, Hercules, CA, USA) and 6–11 
(ImmobilineTM DryStrip; 0.5 × 3 × 180 mm, Amersham 
Pharmacia Biotech, Uppsala, Sweden) on Protean IEF 
Cell System (Bio-Rad). The second dimension was 12% 
polyacrylamide  gel  (acrylamide/bisacrylamide  37.5:1, 
2.6% cross-linker; gel dimension, 20 cm × 20 cm × 1 
mm). All gels in this study were run in quadruplicates 
and the two best gels of each sample were used for image 
analysis, all according to Standard Operating Procedures 
[49, 50]. By identifying each protein at least twice from 
replicated gels, we confirmed the fidelity of our sequence 
of electrophoresis, image analysis, robotic spot excision, 
protein  digestion,  and  protein  identification  by  mass 
spectrometry.
immunofluorescence localization of RSU1 protein 
in colonic fibroblasts
2.5x105 cells were seeded on cover slips in 6 cm 
tissue culture dish overnight. Cells were then washed 3X 
with PBS, fixed in ice-cold methanol, and permeabilized 
with 0.1 % Triton X-100 in PBS. Cells were incubated 
in 2% milk in PBS for 1 hour and then probed with 
antibodies anti-APC (ab15270, rabbit polyclonal, 1:20 to 
1:100, Abcam, MA) and anti-RSU1 (chicken polyclonal, 
1:100-1:1000, GenWay, CA), in antibody dilution buffer 
(0.2% milk in PBS). After three washes with PBS, the 
cells  were  incubated  with  species-specific  secondary 
antibodies conjugated with Alexa Fluor 488, 546, or 555 
(Molecular Probes, CA). The cover slips were mounted 
on glass slides with mounting medium (0.5% N-Propyl 
Gallate, 90% glycerol in PBS), sealed with nail polish, 
and subjected to Z-axis optical sectioning (0.5-0.75 µM/Oncotarget 2011; 2:  197 - 208 206 www.impactjournals.com/oncotarget
section) in a Nikon E800 upright microscope with Zeiss 
Radiance 2000 confocal scanhead using LaserSharp 2000 
software (Bio-Rad, CA).
Real-time PCR
Contaminating DNA in RNA preparations was 
removed  using  TURBO  DNA-free™ (Ambion). RNA 
was  quantified  using  the Agilent  2100  BioAnalyzer  in 
combination with a RNA 6000 Nano LabChip. RNA was 
reverse-transcribed using M-MLV reverse transcriptase 
(Ambion) and a mixture of anchored oligo-dT and 
random decamers. Using Taqman chemistry, 5’-nuclease 
assays were run on a 7900 HT sequence detection system 
(Applied Biosystems). Taqman sets were designed using 
Primer Express™ version 2.0 software from Applied 
Biosystems. The 5′ and 3′ probe ends were labeled with 
reporter  dye  6-FAM  (6-carboxy-fluorescein,  Glenn 
Research) and quencher dye BHQ1 (Black Hole Quencher, 
Biosearch Technologies), respectively. All primers and 
probes were synthesized by the Fox Chase Cancer Center 
Fannie Rippel Biochemistry and Biotechnology Facility. 
PCR master mix from Eurogentec was used for PCR. 
Primer and probe concentrations were 400 nM and 100 
nM respectively. Cycling conditions were 95°C, for 15 
min, followed by 40 (2-steps) cycles (95°C, 15 sec; 60°C, 
60 sec). Cycle threshold (Ct) values were converted to 
quantities (in arbitrary units) using a standard curve (4 
points, 5-fold serial dilutions) established with a calibrator 
sample. For each sample, 2 RT reactions were performed 
with inputs of 50 and 10 ng RNA. An aliquot of the cDNA 
was used for PCR. The assay components were: DJ-1: 
forward GATACTGAAGGAGCAGGAAAACC, reverse 
TGAGCCAACAGAGCAGTAGGA, probe (6-FAM)
CCTGATAGCCGCCATCTGTGCAG(BHQ1). RSU1: 
forward GTCATTATTCTTCTTCGGTGGTTCT, reverse 
TCCGTTCTGAGACATACAAATACCT, probe (6-FAM)
TGGCCTGCATGTGTCTGCCGTA(BHQ1).
Statistical analyses
Statistical analysis of 2D gel images using 16 bit 
pixel intensity information was supported by Progenesis 
Discovery  Workstation  software  (Nonlinear  Dynamics, 
Inc.). Results were edited by an experienced operator. 
With 12 gels in the image analysis of pH 5–8 range, we 
rejected any spot that was missing in more than 2 gels. The 
dynamic range of the spot intensities in this presentation 
was about 600. A cut-off value for 1.5 fold change was 
used to output a list of significant protein changes.
Protein identification
Robotic cutting of protein spots, trypsin digestion, 
automated MALDI-TOF mass spectrometry, and protein 
identification from Swiss-Prot database were previously 
described in detail [49, 50]. The identity and function of 
the genes separating FAP fibroblasts from control were 
explored at the gene ontology databases FatiGO+(http://
babelomics.bioinfo.cipf.es/functional.html) and Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID  http://david.abcc.ncifcrf.gov/).  The  fibroblast 
differential proteome was further compared with the 
FAP crypt differential proteome [4] to determine protein 
changes  in  common  between  crypt  and  fibroblast  that 
may suggest protein changes related to APC heterozygous 
mutation.
Western blotting validation of biomarkers. 
Western blotting in samples of colonic crypt cells 
and colonic primary fibroblast cultures were performed 
for RSU1 and DJ-1 to validate their signatures as primary 
proteomic alterations in the FAP heterozygous state. For 
each sample, 100 µg of protein was resolved on a 1D or 
a 2D gel. Blotting was performed at 200 mA for 2 hours. 
Antibodies used were Anti-RSU1 (chicken polyclonal, 
1:100–1:1000,  GenWay,  CA)  and  anti-DJ-1  (E2.1, 
monoclonal, 1:10, Zymed, Inc., CA). Blocking was done 
in  5%  non-fat  dry  milk/TBS,  first  antibody  anti-DJ-1 
1:200, second antibody goat anti-mouse (Zymed Inc) 
1:2000. Imaging was obtained on Kodak BioMax film 
developed with Bio-Rad ECL reagent.
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